These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 30619311

  • 41. Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive.
    Roberson EDO, Mesa RA, Morgan GA, Cao L, Marin W, Pachman LM.
    Sci Rep; 2022 Jan 07; 12(1):275. PubMed ID: 34997119
    [Abstract] [Full Text] [Related]

  • 42. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
    Nguyen M, Do V, Yell PC, Jo C, Liu J, Burns DK, Wright T, Cai C.
    Acta Neuropathol Commun; 2020 Aug 05; 8(1):125. PubMed ID: 32758284
    [Abstract] [Full Text] [Related]

  • 43. Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood.
    Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H, van Schieveen C, Bakker MH, Klein M, Scholman RC, Spliet W, Ricotti V, Koenen HJ, de Weger RA, Wedderburn LR, van Royen-Kerkhof A, Prakken BJ.
    PLoS One; 2014 Aug 05; 9(8):e105353. PubMed ID: 25157414
    [Abstract] [Full Text] [Related]

  • 44. [Myositis-specific antibodies associated with juvenile dermatomyositis].
    Eising K, Peitz J, Unterwalder N, Meisel C, Horneff G.
    Z Rheumatol; 2018 Oct 05; 77(8):735-740. PubMed ID: 29411095
    [Abstract] [Full Text] [Related]

  • 45. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
    Vignesh P, Barman P, Basu S, Mondal S, Ishran B, Kumrah R, Dod A, Garg R, Rawat A, Singh S.
    Immunol Res; 2023 Feb 05; 71(1):112-120. PubMed ID: 36278969
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.
    Wedderburn LR, Rider LG.
    Best Pract Res Clin Rheumatol; 2009 Oct 05; 23(5):665-78. PubMed ID: 19853831
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients.
    Aikawa NE, Jesus AA, Liphaus BL, Silva CA, Carneiro-Sampaio M, Viana VS, Sallum AM.
    Clin Exp Rheumatol; 2012 Oct 05; 30(1):126-31. PubMed ID: 22261392
    [Abstract] [Full Text] [Related]

  • 54. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
    Yu HH, Chang HM, Chiu CJ, Yang YH, Lee JH, Wang LC, Lin YT, Chiang BL.
    J Microbiol Immunol Infect; 2016 Apr 05; 49(2):264-70. PubMed ID: 25070283
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Clinical and autoantibody phenotypes of juvenile dermatomyositis.
    Boyarchuk O, Kuka A, Yuryk I.
    Reumatologia; 2022 Apr 05; 60(4):281-291. PubMed ID: 36186835
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.